Tracking severe and very severe COPD across Brazil
Official title: Prospective and Multicentric Cohort Study of Severe and Very Severe Chronic Obstructive Pulmonary Disease (COPD) in Brazil (SCOPe).
Run by Hospital Israelita Albert Einstein · NCT06724315 · Data updated 2026-11-12
This project will follow people with severe or very severe COPD in Brazil for one year to see which groups have higher risk of exacerbations, hospital stays, heart problems, or death.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 693 (estimated) |
| Sponsor | Hospital Israelita Albert Einstein Academic / other |
| Locations | 1 site (São Paulo, São Paulo) |
| Status | Recruiting |
| Started | January 31, 2025 |
| Main results expected | July 15, 2026 |
| Study ends | December 15, 2026 |
| Registry record updated | June 5, 2025 |
| Trial ID | NCT06724315 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults in Brazil with symptomatic severe or very severe COPD by GOLD criteria (GOLD B with mMRC≥2 or CAT≥10, GOLD E with ≥2 moderate or ≥1 severe exacerbation, or GOLD 3–4 with FEV1 <50%) who can attend study visits and telephone follow-up are ideal candidates.
✕Probably not a fit
Patients with mild or moderate COPD or those with excluded conditions (extensive interstitial lung disease >50% on HRCT, severe pulmonary hypertension on triple therapy, or active cancer receiving systemic therapy) are unlikely to benefit from this observational follow-up.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, non-interventional multicenter cohort that will enroll consecutive patients with severe or very severe COPD at sites representing Brazil's geographic regions. Participants will have on-site visits at enrollment, 6 and 12 months, with telephone check-ins at 3 and 9 months, and clinical events (exacerbations, hospitalizations, cardiovascular events, deaths) will be recorded and adjudicated. Data collected will include symptom scores (CAT/CAAT), spirometry-defined severity, exacerbation history, and regional exposure factors such as tobacco, biomass, and air pollution. The goal is to identify subgroups at especially high risk who could be targets for future interventions.
Why it matters
Potential benefit: If successful, the project could help doctors identify which patients with severe COPD are most likely to have future exacerbations or complications so care can be targeted to those at highest risk.
How similar studies have gone: Large population cohorts such as PLATINO and other longitudinal COPD cohorts have identified risk patterns for exacerbations and mortality, but tailored interventions for the highest-risk subgroups remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Severe, very severe and symptomaitc COPD, according to GOLD definition: exposure, FEV1/FVC ratio \<0,7: * GOLD B (mMRC\>=2, CAT\>=10), OR * GOLD E (\>=2 moderate exacerbations or 1 severe), OR * GOLD 3 and 4 (FEV1 \<50%). Exclusion Criteria: Severe interstitial lung disease (extent \>50% on HRCT), OR Severe pulmonary hypertension (on triple therapy), OR Active cancer - undergoing systemic therapy.
Where it's running
-
Hospital Israelita Albert Einstein (HIAE)
São Paulo, São Paulo, Brazil Recruiting
Study contacts
- Study coordinator: Francisco JN Mazon, MD
- Email: francisco.mazon@einstein.br
- Phone: +55 11 21511233
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Enhanced COPD care for people being checked for lung cancer
This project will test whether finding and treating COPD early in people being checked for possible lung cancer helps symptoms, lung function, and overall care.
-
High-Flow Nasal Cannula vs Noninvasive Ventilation in COPD with Hypercapnia
This study tests whether a high-flow nasal cannula can better support gas exchange and comfort compared with noninvasive ventilation in COPD patients with mild-to-moderate elevated CO2.
-
Risk-based lung cancer screening in COPD patients using ML and clinical models
This study tests whether a PLCOm2012 risk model plus a machine learning model can spot COPD patients at high risk for lung cancer to see if they benefit from low-dose CT screening.
-
Biologics for Type 2 Inflammation in Asthma and COPD in Real World
This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.
-
Nebulized vs handheld maintenance therapy for COPD patients with limited benefit from inhalers
This trial tests whether switching to a breath-enhanced nebulizer with similar COPD meds helps people who don’t get enough relief from their current handheld inhalers.
-
New breathing tests to diagnose airway disease in hospital and community settings
This study tests whether newer breathing tests can correctly diagnose COPD and airway disease as well as standard spirometry, using tests like capnography and oscillometry in hospital and community settings.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.